COVID-19 -- Worldwide/Unknown
Abstract
--------
Background
Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (COVID-19).
Methods
We conducted a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia. Patients were randomly assigned in a 1:1 ratio to receive intravenous
Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?7920708&promed&0
No comments:
Post a Comment